Skip to main content
Signal8

Jaguar Health, Inc. (JAGX) Form 8-K — Nov 16, 2026

$JAGXForm 8-KItems 2.02, 9.01Filed Nov 16, 2026, 9:15 AM ET0001193125-26-462345Original filing

Jaguar Health reported Q3 2026 total net revenue of $2.34 million, down 24% year over year, as prescription product revenue fell 81.9% to $551K following the January 2026 licensing of Mytesi and Canalevia-CA1 U.S. commercial rights to Future Pak. Net loss improved 39.6% to $5.83 million from $9.65 million a year ago, and non-GAAP recurring EBITDA loss narrowed to $5.0 million from $9.0 million, helped by the dissolution of the salesforce and roughly $2.0 million lower operating expenses under the Future Pak deal.

Key figures

Revenue
2343000
Guidance
Planned NDA filing for crofelemer for MVID in mid-2027
Revenue Yoy
-24.0%
Deferred revenue
$425,000
Holdback received
~$1.8 million
Loss from operations
-$6.023M (vs -$7.238M, +16.8% improvement)
Debt reduction q3 2026
$10.1 million
Future pak upfront payment
$16 million (recognized Q1 2026)
Non gaaap recurring ebitda
-$5.032M (vs -$9.025M)
Gain on debt extinguishment
$0.558M (Streeterville New Note)
Product revenue net q3 2026
$551K (vs $3.04M Q3 2025, -81.9%)
License and grant revenue q3 2026
$1.792M (vs $42K Q3 2025)
Buy back option termination payment
$3 million

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.